R. Fonseca, P. Bergsagel, J. Drach, J. Shaughnessy, and N. Gutierrez, International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, vol.91, issue.12, pp.2210-2221, 2009.
DOI : 10.1016/j.beha.2007.08.004

F. Zhan, Y. Huang, S. Colla, J. Stewart, and I. Hanamura, The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.
DOI : 10.1182/blood-2005-11-013458

J. Shaughnessy, . Jr, F. Zhan, B. Burington, Y. Huang et al., A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, vol.109, issue.6, pp.2276-2284, 2007.
DOI : 10.1182/blood-2006-07-038430

O. Decaux, L. Lode, F. Magrangeas, C. Charbonnel, and W. Gouraud, Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du My??lome, Journal of Clinical Oncology, vol.26, issue.29, pp.4798-4805, 2008.
DOI : 10.1200/JCO.2007.13.8545

D. Hose, T. Reme, T. Hielscher, J. Moreaux, and T. Meissner, Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, issue.1, pp.87-95, 2011.
DOI : 10.3324/haematol.2010.030296

D. Hose, T. Reme, T. Meissner, J. Moreaux, and A. Seckinger, Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma, Blood, vol.113, issue.18, pp.4331-4340, 2009.
DOI : 10.1182/blood-2008-09-178350
URL : https://hal.archives-ouvertes.fr/inserm-00368414

A. Seckinger, T. Meissner, J. Moreaux, H. Goldschmidt, and G. Fuhler, Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis, Oncogene, vol.83, issue.44, pp.3866-3879, 2009.
DOI : 10.1182/blood.V99.5.1745
URL : https://hal.archives-ouvertes.fr/inserm-00437705

A. Kassambara, D. Hose, J. Moreaux, B. Walker, and A. Protopopov, Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma, Haematologica, vol.97, issue.4, pp.622-630, 2012.
DOI : 10.3324/haematol.2011.046821
URL : https://hal.archives-ouvertes.fr/inserm-00727008

J. Moreaux, B. Klein, R. Bataille, G. Descamps, and S. Maiga, A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-582, 2011.
DOI : 10.3324/haematol.2010.033456
URL : https://hal.archives-ouvertes.fr/inserm-00550232

F. Chibon, P. Lagarde, S. Salas, G. Perot, and V. Brouste, Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity, Nature Medicine, vol.99, issue.7, pp.781-787, 2010.
DOI : 10.1038/nm.2174

F. Lemee, V. Bergoglio, A. Fernandez-vidal, A. Machado-silva, and M. Pillaire, DNA polymerase ?? up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability, Proceedings of the National Academy of Sciences, vol.107, issue.30, pp.13390-13395, 2010.
DOI : 10.1073/pnas.0910759107

M. Pillaire, J. Selves, K. Gordien, P. Gourraud, and C. Gentil, A ???DNA replication??? signature of progression and negative outcome in colorectal cancer, Oncogene, vol.33, issue.6, pp.876-887, 2010.
DOI : 10.1083/jcb.200602108
URL : https://hal.archives-ouvertes.fr/hal-00459069

S. Carter, A. Eklund, I. Kohane, L. Harris, and Z. Szallasi, A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers, Nature Genetics, vol.1, issue.9, pp.1043-1048, 2006.
DOI : 10.1038/nrc1802

J. Christensen, P. Jensen, I. Kristensen, N. Abildgaard, and M. Lodahl, Characterization of potential CD138 negative myeloma "stem cells", Haematologica, vol.97, issue.6, pp.18-20, 2012.
DOI : 10.3324/haematol.2011.043125

D. Chiron, S. Surget, S. Maiga, R. Bataille, and P. Moreau, The peripheral CD138+ population but not the CD138??? population contains myeloma clonogenic cells in plasma cell leukaemia patients, British Journal of Haematology, vol.95, issue.5, pp.679-683, 2012.
DOI : 10.1111/j.1365-2141.2011.08904.x

P. Greipp, N. Raymond, R. Kyle, O. Fallon, and W. , Multiple myeloma: significance of plasmablastic subtype in morphological classification, Blood, vol.65, pp.305-310, 1985.

C. Kretschmer, A. Sterner-kock, F. Siedentopf, W. Schoenegg, and P. Schlag, Identification of early molecular markers for breast cancer, Molecular Cancer, vol.10, issue.1, p.15, 2011.
DOI : 10.1186/1476-4598-10-15

Y. Harada, M. Kanehira, Y. Fujisawa, R. Takata, and T. Shuin, Cell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells, Cancer Research, vol.70, issue.14, pp.5829-5839, 2010.
DOI : 10.1158/0008-5472.CAN-10-0255

H. Okayama, T. Kohno, Y. Ishii, Y. Shimada, and K. Shiraishi, Identification of Genes Up-regulated in ALK-positive and EGFR/KRAS/ALKnegative Lung Adenocarcinomas, Cancer Res, 2011.

M. Kanehira, Y. Takata, . Shuin, . Miki, and . Fujioka, Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis, Oncogene, vol.26, issue.44, pp.6448-6455, 2007.
DOI : 10.1158/0008-5472.CAN-05-0120

G. Jego, N. Robillard, D. Puthier, M. Amiot, and F. Accard, Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, Blood, vol.94, pp.701-712, 1999.

M. Jourdan, A. Caraux, D. Vos, J. Fiol, G. Larroque et al., An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization, Blood, vol.114, issue.25, pp.5173-5181, 2009.
DOI : 10.1182/blood-2009-07-235960
URL : https://hal.archives-ouvertes.fr/inserm-00446133

O. Cazzalini, A. Scovassi, M. Savio, L. Stivala, and E. Prosperi, Multiple roles of the cell cycle inhibitor p21CDKN1A in the DNA damage response, Mutation Research/Reviews in Mutation Research, vol.704, issue.1-3, pp.12-20, 2010.
DOI : 10.1016/j.mrrev.2010.01.009

J. Smith, L. Tho, N. Xu, and D. Gillespie, The ATM???Chk2 and ATR???Chk1 Pathways in DNA Damage Signaling and Cancer, Adv Cancer Res, vol.108, pp.73-112, 2010.
DOI : 10.1016/B978-0-12-380888-2.00003-0

R. Hill and P. Lee, The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet?, Cell Cycle, vol.9, issue.17, pp.3460-3469, 2010.
DOI : 10.4161/cc.9.17.13043

L. Medugno, F. Florio, D. Cegli, R. Grosso, M. Lupo et al., The Kr??ppel-like zinc-finger protein ZNF224 represses aldolase A gene transcription by interacting with the KAP-1 co-repressor protein, Gene, vol.359, pp.35-43, 2005.
DOI : 10.1016/j.gene.2005.06.021

J. Friedman, W. Fredericks, D. Jensen, D. Speicher, and X. Huang, KAP-1, a novel corepressor for the highly conserved KRAB repression domain., Genes & Development, vol.10, issue.16, pp.2067-2078, 1996.
DOI : 10.1101/gad.10.16.2067

I. Vitale, L. Galluzzi, M. Castedo, and G. Kroemer, Mitotic catastrophe: a mechanism for avoiding genomic instability, Nature Reviews Molecular Cell Biology, vol.29, issue.6, pp.385-392, 2011.
DOI : 10.1038/nrm3115

A. Kallies, J. Hasbold, K. Fairfax, C. Pridans, and D. Emslie, Initiation of Plasma-Cell Differentiation Is Independent of the Transcription Factor Blimp-1, Immunity, vol.26, issue.5, pp.555-566, 2007.
DOI : 10.1016/j.immuni.2007.04.007

K. Ancelin, U. Lange, P. Hajkova, R. Schneider, and A. Bannister, Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells, Nature Cell Biology, vol.418, issue.6, pp.623-630, 2006.
DOI : 10.1038/ncb1413

A. Lupo, E. Cesaro, G. Montano, P. Izzo, and P. Costanzo, ZNF224: Structure and role of a multifunctional KRAB-ZFP protein, The International Journal of Biochemistry & Cell Biology, vol.43, issue.4, pp.470-473, 2011.
DOI : 10.1016/j.biocel.2010.12.020

M. Jourdan, A. Caraux, G. Caron, N. Robert, and G. Fiol, Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation, The Journal of Immunology, vol.187, issue.8, pp.3931-3941, 2011.
DOI : 10.4049/jimmunol.1101230
URL : https://hal.archives-ouvertes.fr/hal-00743965

D. Hose, T. Reme, T. Hielscher, J. Moreaux, and T. Messner, Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, issue.1, pp.87-95, 2011.
DOI : 10.3324/haematol.2010.030296

P. Greipp, T. Leong, J. Bennett, J. Gaillard, and B. Klein, Plasmablastic morphology-An independent prognostic factor with clinical and laboratory correlates: eastern cooperative oncology group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group, Process Citation], pp.2501-2507, 1998.

X. Zhang, J. Gaillard, N. Robillard, Z. Lu, and Z. Gu, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994.

Z. Gu, J. Vos, C. Rebouissou, J. M. Zhang, and X. , Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-197, 2000.
DOI : 10.1038/sj.leu.2401632

C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, and V. Costes, A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma, Blood, vol.91, pp.4727-4737, 1998.

D. Vos, J. Thykjaer, T. Tarte, K. Ensslen, M. Raynaud et al., Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays, Oncogene, vol.99, issue.44, pp.6848-6857, 2002.
DOI : 10.1038/sj.onc.1205868

F. Cremer, J. Bila, I. Buck, M. Kartal, and D. Hose, Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics, Genes, Chromosomes and Cancer, vol.40, issue.2, pp.194-203, 2005.
DOI : 10.1002/gcc.20231

B. Barlogie, G. Tricot, E. Rasmussen, E. Anaissie, and F. Van-rhee, Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies, Blood, vol.107, issue.7, pp.2633-2638, 2006.
DOI : 10.1182/blood-2005-10-4084

J. Moreaux, F. Cremer, T. Reme, M. Raab, and K. Mahtouk, The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, pp.1021-1030, 2005.
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406

M. Jourdan, K. Mahtouk, J. Veyrune, G. Couderc, and G. Fiol, Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors, Eur Cytokine Netw, vol.16, pp.57-64, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00130868

T. Reme, D. Hose, D. Vos, J. Vassal, A. Poulain et al., A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, p.16, 2008.
DOI : 10.1186/1471-2105-9-16
URL : https://hal.archives-ouvertes.fr/inserm-00268075

T. Le-carrour, S. , S. Tondeur, L. Lhermitte, N. Lamb et al., Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data, The Open Bioinformatics Journal, vol.4, issue.1, pp.5-10, 2010.
DOI : 10.2174/1875036201004010005